1 May 2017 - Latest MSD biosimilar secures TGA approval.

MSD has today announced its intention to launch biosimilar Renflexis (infliximab) in the second half of 2017 following approval by the Therapeutics Goods Administration.

Renflexis is the second infliximab biosimilar to receive TGA approval. In adults, Renflexis is indicated for the treatment of moderate to severe Crohn's disease and moderate to severe ulcerative colitis in adults and in children adolescents (6 to 17 years) who have had an inadequate response to conventional therapies. 

Renflexis is also indicated, in adults, for the treatment of rheumatoid arthritis, ankylosing spondylitis, psoriatic arthritis, moderate to severe psoriasis and refractory fistulising Crohn's disease. Renflexis should be given in combination with methotrexate for the treatment of rheumatoid arthritis, and alone, or in combination with methotrexate, for the treatment of psoriatic arthritis.

Read MSD press release